NASDAQ · TARA
Healthcare · Biotechnology
$2.76
Up+$0.11 (+3.96%)
Updated Oct 10, 2026, 3:56 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TARA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
TARA closed at $2.76 after 21 trading sessions, down 27.88% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $2.69 | $2.785 | $2.65 | $2.755 | 1.04M |
| Oct 8, 2026 | $2.59 | $2.69 | $2.515 | $2.65 | 1.22M |
| Oct 7, 2026 | $2.54 | $2.67 | $2.51 | $2.59 | 731.35K |
| Oct 6, 2026 | $2.63 | $2.70 | $2.53 | $2.555 | 803.56K |
| Oct 5, 2026 | $2.71 | $2.72 | $2.565 | $2.63 | 1.4M |
| Oct 2, 2026 | $2.81 | $2.95 | $2.62 | $2.70 | 1.91M |
| Oct 1, 2026 | $3.06 | $3.10 | $2.745 | $2.76 | 5M |
| Sep 30, 2026 | $3.23 | $3.30 | $2.98 | $3.05 | 8.82M |
| Sep 29, 2026 | $3.33 | $3.345 | $3.21 | $3.21 | 391.47K |
| Sep 28, 2026 | $3.27 | $3.386 | $3.19 | $3.25 | 431.13K |
| Sep 25, 2026 | $3.35 | $3.44 | $3.23 | $3.28 | 552.94K |
| Sep 24, 2026 | $3.54 | $3.55 | $3.315 | $3.35 | 661.97K |
| Sep 23, 2026 | $3.69 | $3.75 | $3.44 | $3.54 | 882.84K |
| Sep 22, 2026 | $3.55 | $3.88 | $3.55 | $3.68 | 2.89M |
| Sep 21, 2026 | $3.59 | $3.68 | $3.47 | $3.51 | 735.47K |
| Sep 18, 2026 | $3.69 | $3.725 | $3.45 | $3.55 | 3.95M |
| Sep 17, 2026 | $3.65 | $3.76 | $3.62 | $3.70 | 654.16K |
| Sep 16, 2026 | $3.78 | $3.87 | $3.615 | $3.62 | 2.06M |
| Sep 15, 2026 | $3.91 | $3.94 | $3.74 | $3.75 | 901.08K |
| Sep 14, 2026 | $3.83 | $4.015 | $3.818 | $3.91 | 735.18K |
| Sep 11, 2026 | $3.83 | $3.95 | $3.81 | $3.82 | 532.03K |
The latest Smart Investors Daily articles mentioning TARA.
Company
Market Activity
Research & News
TARA research
Company profile and research snapshot.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 20, 2026 | Oppenheimer | Outperform | — |
| May 14, 2026 | JP Morgan | Overweight | — |
| Apr 29, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 4, 2026 | JP Morgan | Overweight | — |
| Feb 10, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 4, 2026
JP Morgan analyst Brian Cheng initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating and announces Price Target of $27.
SeekingAlpha · Feb 26, 2026
Yahoo · Feb 25, 2026
Protara Therapeutics (NASDAQ:TARA) shared updated interim data from its ongoing Phase 2, open-label ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease. Management said
SeekingAlpha · Feb 24, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TARA.
